Eton Pharmaceuticals Seeks FDA Approval to Expand KHINDIVI Indication to Younger Pediatric Patients — Eton Pharmaceuticals, Inc.

Event summary

Eton Pharmaceuticals submitted a Prior Approval Supplement (PAS) to the FDA to expand KHINDIVI's indication to pediatric patients under five years old.
The new formulation demonstrated bioequivalence to ALKINDI SPRINKLE, a competing hydrocortisone product.
Approval could come in the first half of 2027, potentially accelerating KHINDIVI adoption.
KHINDIVI is currently approved for patients aged five and older with adrenocortical insufficiency.

The big picture

Eton Pharmaceuticals' submission to expand the indication of KHINDIVI reflects a strategic push into the under-served pediatric adrenal insufficiency market. The move aligns with broader industry trends toward developing specialized treatments for rare diseases, particularly in younger patient populations where FDA-approved options are limited. Success could position Eton as a key player in this niche, though regulatory and competitive hurdles remain.

What we're watching

Regulatory Timeline: Whether the FDA will approve the expanded indication by the first half of 2027 as projected.
Market Penetration: How expanding KHINDIVI’s age range will impact adoption rates among pediatric patients and healthcare providers.
Competitive Dynamics: The potential shift in market share between KHINDIVI and ALKINDI SPRINKLE if approval is granted.